Cleaved caspase-3 immunocytochemical staining for pancreatic islets and pancreatic endocrine tumors: A potential marker for biological malignancy

Islets

Volumn 2, Issue 2, 2010, Pages

  Tomita, Tatsuo ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Caspase 3; Immunocytochemistry; Pancreatic islets and pancreatic endocrine tumors

Indexed keywords

CASPASE 3; CLEAVED CASPASE 3; UNCLASSIFIED DRUG; TUMOR MARKER;

APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; GASTRINOMA; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; INSULINOMA; PANCREAS ISLET CELL; PANCREAS ISLET CELL TUMOR; PANCREATIC PEPTIDOMA; SOMATOSTATINOMA; ADOLESCENT; ADULT; AGED; ANIMAL; ENDOCRINE SYSTEM EXAMINATION; EVALUATION; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; NEUROENDOCRINE TUMOR; PANCREAS ISLET; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY; PROTEIN PROCESSING; RABBIT; STAINING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CASPASE 3; DIAGNOSTIC TECHNIQUES, ENDOCRINE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INSULINOMA; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RABBITS; STAINING AND LABELING; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 85046915675     PISSN: 19382014     EISSN: 19382022     Source Type: Journal    
DOI: 10.4161/isl.2.2.10807     Document Type: Article

References (30)

1. Martin SJ, Green DR. Protease activation during apoptosis: death by thousand cuts? Cell 1995; 82:349-52.
2. Cohen GM. Caspases: the excursions of apoptosis. Biochem J 1997; 326:1-16.
3. Hirata H, Takahashi A, Kobayashi S, Yonehara S, Sawai H, et al. Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis. J Exp Med 1998; 187:587-600.
4. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, et al. Yama/CPP32β, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly (ADP-ribose) polymerase. Cell 1995; 81:801-9.
5. Gown AM, Willingham MC. Improved detection of apoptotic cells in archival paraffin sections: Immunohistochemistry using antibodies to cleaved caspase 3. J Histochem Cytochem 2002; 50:449-54.
6. Cleaved Caapase-3 (Asp 175) Antibody, Cell Signaling Technology, Publication # 9661, Cell Signaling Technology, Beverly MA 2006; 1-7.
7. Butler AE, Jansen J, Bonner-Weir S, Ritzel R, Rizza RA, et al. β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52:102-10.
8. Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic-β cell death in type 1 and type 2 diabetes. Diabetes 2005; 54:97-107.
9. Tomita T. Caspase-3 immunocytochemical staining for pancreatic islets and pancreatic endocrine tumors. Hum Pathol 2009; 40:1050-2.
10. Tomita T, Iwata K. Gelatinases and inhibitors of gelatinases in pancreatic islets and islet cell tumors. Mod Pathol 1997; 10:47-54.
11. Tomita T. Metallothionein in pancreatic endocrine tumors. Mod Pathol 2000; 13:389-95.
12. Heitz PU, Komninoth P, Perren A, et al. Pancreatic endocrine tumors: Introduction. In: World Health Organization of Tumours, Pathology and Genetics of Tumors of Endocrine Organs. DeLellis RA, Lloyd RV, Heitz PU, Eng C, eds. IARC Press, Lyon 2004; 177-82.
13. Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors. The WHO classification. Ann NY Acad Sci 2004; 1014:13-27.
14. Tomita T, Friesen SR, Kimmel JR, Pollock HG. Pancreatic polypeptide-secreting islet cell tumors. Am J Pathol 1983; 113:134-42.
15. Tomita T, Friesen S, Pollock G. PP-secreting tumors. In: Endocrine Pathology of Gut and Pancreas. In: Dayal Y, Editor, Endocrine pathology of gut and pancreas. Boca Raton: CRC Press 1991; 279-304.
16. Hruban RH, Pitna MB, Klimstra DS. Tumors of the pancreas. In: AFIP Atlas of Tumor Pathology, AFIP, Washington DC 2007; 4:251-304.
17. Tomita T, Friesen SR, Kimmel JR. Pancreatic polypeptide secreting islet cell tumor. A conclusive follow-up study. Cancer 1986; 57:129-33.
18. Milliga CE, Prevette D, Yagimura H, Homma S, et al. Peptide inhibitors of the ICE proteinase family arrest programmed cell death of motorneurons in vivo and in vitro. Neuron 1995; 15:385-93.
19. Enari M, Talanian RV, Wong WW, Nagata S. Sequential activation of ICE-like and CPP32-like proteinases during Fas-mediated apoptosis. Nature 1996; 380:723-6.
20. Yamada K, Ichikawa F, Ishikawa-Shigemoto S, Yuan X, Nonaka K. Essential role of caspase-3 in apoptosis of mouse β cells transfected with human Fas. Diabetes 1999; 48:478-83.
21. Marchetti P, DelGuerra S, Marselli L, et al. Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by Metform. J Clin Endocrinol Metab 2004; 89:5535-41.
22. Schmitt AM, Anlauf M, Rousson V, et al. WHO 2004 criteria and CK 19 are reliable prognostic markers in pancreatic endocrine tumors. Am J Surg Path 2007; 31:1677-82.
23. La Rosa S, Klersy C, Uccella S, Dainese L, Albarello L, Sonzogni A, et al. Improved histologc and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Hum Path 2009; 40:30-40.
24. Tomita T. Amylin in pancreatic islets and pancreatic endocrine neoplasms. Pathol Int 2003; 53:591-5.
25. Jones MC. Therapies for diabetes: pramlintide and exanatide. Am Fam Physicians 2007; 75:1831-5.
26. Tomita T. New markers for pancreatic islets and islet cell tumors. Pathol Int 2002; 52:425-32.
27. Birdal-Hansen T, Moore WGI, Bodden MK, Mindsot LJ, Birkedal - Hansen B, Decaro A, et al. Matrix metalloproteinases-Review. Crit Rev Oral Biol 1993; 4:197-250.
28. Perez SE, Cano DA, Aopick T, Rougier JP, Werb Z, Hebrok M. Matrix metalloproteinses 2 and 9 are dispensable for pancreatic islet formation and function in vivo. Diabetes 2005; 54:694-701.
29. Fingleton B. Matrix metalloproteinases as valid clinical targets. Curr Pharmacol Des 2007; 13:333-46.
30. Taylor CR, Levenson RM. Quantification of immunohistochemistry - issues concerning methods, utility and semi quantitative assessment II. Histopath 2006; 49:411-24.